Annual SG&A
$2.63 B
+$515.40 M+24.36%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual selling, general & administrative expenses is currently $2.63 billion, with the most recent change of +$515.40 million (+24.36%) on 31 December 2023. During the last 3 years, it has risen by +$1.29 billion (+95.49%). REGN annual SG&A is now at all-time high.REGN Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$714.40 M
-$44.40 M-5.85%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly selling, general & administrative expenses is currently $714.40 million, with the most recent change of -$44.40 million (-5.85%) on 30 September 2024. Over the past year, it has increased by +$73.90 million (+11.54%). REGN quarterly SG&A is now -5.85% below its all-time high of $758.80 million, reached on 30 June 2024.REGN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$115.41 B
+$4.65 B+4.20%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM selling, general & administrative expenses is currently $115.41 billion, with the most recent change of +$4.65 billion (+4.20%) on 30 September 2024. Over the past year, it has increased by +$112.86 billion (+4418.71%). REGN TTM SG&A is now at all-time high.REGN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.4% | +11.5% | +4418.7% |
| 3 y3 years | +95.5% | +60.5% | +7256.7% |
| 5 y5 years | +133.4% | +134.7% | +10000.0% |
REGN Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +95.5% | -5.8% | +60.5% | at high | +110.8% |
| 5 y | 5 years | at high | +133.4% | -5.8% | +135.4% | at high | +391.4% |
| alltime | all time | at high | >+9999.0% | -5.8% | >+9999.0% | at high | +2447.8% |
Regeneron Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $714.40 M(-5.9%) | $2.90 B(+2.6%) |
| June 2024 | - | $758.80 M(+10.1%) | $2.83 B(+3.9%) |
| Mar 2024 | - | $689.00 M(-6.6%) | $2.72 B(+3.3%) |
| Dec 2023 | $2.63 B(+24.4%) | $737.70 M(+15.2%) | $2.63 B(+3.0%) |
| Sept 2023 | - | $640.50 M(-1.8%) | $2.55 B(+4.6%) |
| June 2023 | - | $652.00 M(+8.5%) | $2.44 B(+7.8%) |
| Mar 2023 | - | $601.10 M(-9.0%) | $2.27 B(+7.1%) |
| Dec 2022 | $2.12 B(+15.9%) | $660.50 M(+24.8%) | $2.12 B(+5.0%) |
| Sept 2022 | - | $529.10 M(+11.1%) | $2.02 B(+4.4%) |
| June 2022 | - | $476.30 M(+5.8%) | $1.93 B(+3.3%) |
| Mar 2022 | - | $450.00 M(-19.6%) | $1.87 B(+2.4%) |
| Dec 2021 | $1.82 B(+35.6%) | $559.60 M(+25.8%) | $1.82 B(+16.3%) |
| Sept 2021 | - | $445.00 M(+7.3%) | $1.57 B(+8.1%) |
| June 2021 | - | $414.70 M(+2.2%) | $1.45 B(+4.8%) |
| Mar 2021 | - | $405.60 M(+33.6%) | $1.38 B(+2.8%) |
| Dec 2020 | $1.35 B(+0.3%) | $303.50 M(-7.2%) | $1.35 B(-9.9%) |
| Sept 2020 | - | $326.90 M(-6.1%) | $1.49 B(+1.5%) |
| June 2020 | - | $348.30 M(-5.2%) | $1.47 B(+3.8%) |
| Mar 2020 | - | $367.30 M(-18.7%) | $1.42 B(+5.7%) |
| Dec 2019 | $1.34 B(+19.0%) | $451.80 M(+48.4%) | $1.34 B(+40.9%) |
| Sept 2019 | - | $304.40 M(+3.3%) | $952.40 M(-6.4%) |
| June 2019 | - | $294.60 M(+1.2%) | $1.02 B(-6.5%) |
| Mar 2019 | - | $291.10 M(+367.3%) | $1.09 B(-3.5%) |
| Dec 2018 | $1.13 B(-14.6%) | $62.30 M(-83.1%) | $1.13 B(-23.6%) |
| Sept 2018 | - | $369.20 M(+1.2%) | $1.47 B(+4.4%) |
| June 2018 | - | $364.80 M(+10.3%) | $1.41 B(+4.3%) |
| Mar 2018 | - | $330.80 M(-19.3%) | $1.35 B(+2.6%) |
| Dec 2017 | $1.32 B(+12.1%) | $409.88 M(+33.6%) | $1.32 B(+6.8%) |
| Sept 2017 | - | $306.77 M(-0.0%) | $1.24 B(+3.1%) |
| June 2017 | - | $306.91 M(+3.4%) | $1.20 B(+1.3%) |
| Mar 2017 | - | $296.85 M(-8.9%) | $1.18 B(+0.6%) |
| Dec 2016 | $1.18 B(+40.4%) | $325.94 M(+20.7%) | $1.18 B(+2.7%) |
| Sept 2016 | - | $270.05 M(-7.5%) | $1.15 B(+5.5%) |
| June 2016 | - | $292.04 M(+0.8%) | $1.09 B(+12.1%) |
| Mar 2016 | - | $289.68 M(-1.8%) | $969.21 M(+15.6%) |
| Dec 2015 | $838.53 M(+61.5%) | $294.95 M(+40.5%) | $838.53 M(+16.6%) |
| Sept 2015 | - | $209.99 M(+20.3%) | $718.88 M(+10.1%) |
| June 2015 | - | $174.59 M(+9.8%) | $652.89 M(+13.5%) |
| Mar 2015 | - | $158.99 M(-9.3%) | $575.03 M(+10.7%) |
| Dec 2014 | $519.27 M(+49.9%) | $175.31 M(+21.7%) | $519.27 M(+17.2%) |
| Sept 2014 | - | $144.00 M(+48.9%) | $443.02 M(+11.7%) |
| June 2014 | - | $96.73 M(-6.3%) | $396.63 M(+6.5%) |
| Mar 2014 | - | $103.23 M(+4.2%) | $372.36 M(+7.5%) |
| Dec 2013 | $346.39 M(+64.4%) | $99.06 M(+1.5%) | $346.39 M(+13.5%) |
| Sept 2013 | - | $97.61 M(+34.7%) | $305.07 M(+19.9%) |
| June 2013 | - | $72.46 M(-6.2%) | $254.34 M(+10.8%) |
| Mar 2013 | - | $77.26 M(+33.8%) | $229.59 M(+8.9%) |
| Dec 2012 | $210.75 M(+79.7%) | $57.74 M(+23.2%) | $210.75 M(+11.3%) |
| Sept 2012 | - | $46.88 M(-1.7%) | $189.37 M(+8.0%) |
| June 2012 | - | $47.70 M(-18.4%) | $175.40 M(+15.2%) |
| Mar 2012 | - | $58.43 M(+60.7%) | $152.28 M(+29.9%) |
| Dec 2011 | $117.26 M(+79.8%) | $36.35 M(+10.4%) | $117.26 M(+15.5%) |
| Sept 2011 | - | $32.92 M(+33.9%) | $101.55 M(+20.5%) |
| June 2011 | - | $24.59 M(+5.0%) | $84.30 M(+13.3%) |
| Mar 2011 | - | $23.41 M(+13.4%) | $74.39 M(+14.1%) |
| Dec 2010 | $65.20 M(+23.2%) | $20.64 M(+31.8%) | $65.20 M(+5.9%) |
| Sept 2010 | - | $15.66 M(+6.7%) | $61.59 M(+4.8%) |
| June 2010 | - | $14.68 M(+3.2%) | $58.77 M(+5.5%) |
| Mar 2010 | - | $14.22 M(-16.5%) | $55.73 M(+5.3%) |
| Dec 2009 | $52.92 M(+8.3%) | $17.03 M(+32.6%) | $52.92 M(+8.2%) |
| Sept 2009 | - | $12.84 M(+10.4%) | $48.91 M(+3.1%) |
| June 2009 | - | $11.63 M(+1.9%) | $47.44 M(-3.8%) |
| Mar 2009 | - | $11.42 M(-12.3%) | $49.31 M(+0.8%) |
| Dec 2008 | $48.88 M(+29.1%) | $13.02 M(+14.6%) | $48.91 M(+3.3%) |
| Sept 2008 | - | $11.37 M(-15.8%) | $47.33 M(+4.6%) |
| June 2008 | - | $13.49 M(+22.4%) | $45.25 M(+11.2%) |
| Mar 2008 | - | $11.02 M(-3.6%) | $40.69 M(+7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2007 | $37.87 M(+46.2%) | $11.44 M(+23.1%) | $37.87 M(+11.2%) |
| Sept 2007 | - | $9.29 M(+4.0%) | $34.05 M(+10.6%) |
| June 2007 | - | $8.94 M(+8.9%) | $30.78 M(+9.4%) |
| Mar 2007 | - | $8.20 M(+7.5%) | $28.15 M(+8.7%) |
| Dec 2006 | $25.89 M(+1.6%) | $7.63 M(+26.7%) | $25.89 M(+2.9%) |
| Sept 2006 | - | $6.02 M(-4.4%) | $25.16 M(-0.8%) |
| June 2006 | - | $6.30 M(+5.9%) | $25.36 M(+0.3%) |
| Mar 2006 | - | $5.95 M(-13.8%) | $25.28 M(-0.8%) |
| Dec 2005 | $25.48 M(+49.3%) | $6.89 M(+10.9%) | $25.48 M(+8.7%) |
| Sept 2005 | - | $6.22 M(+0.0%) | $23.43 M(+9.5%) |
| June 2005 | - | $6.22 M(+1.1%) | $21.40 M(+10.2%) |
| Mar 2005 | - | $6.15 M(+26.6%) | $19.42 M(+13.8%) |
| Dec 2004 | $17.06 M(+15.4%) | $4.85 M(+16.0%) | $17.06 M(+3.7%) |
| Sept 2004 | - | $4.18 M(-1.2%) | $16.45 M(+3.7%) |
| June 2004 | - | $4.24 M(+11.7%) | $15.86 M(+4.9%) |
| Mar 2004 | - | $3.79 M(-10.5%) | $15.12 M(+2.2%) |
| Dec 2003 | $14.79 M(+18.0%) | $4.24 M(+17.7%) | $14.79 M(+6.3%) |
| Sept 2003 | - | $3.60 M(+3.2%) | $13.91 M(+6.0%) |
| June 2003 | - | $3.49 M(+0.8%) | $13.12 M(+4.2%) |
| Mar 2003 | - | $3.46 M(+2.8%) | $12.59 M(+0.5%) |
| Dec 2002 | $12.53 M(+30.4%) | $3.37 M(+19.7%) | $12.53 M(+5.3%) |
| Sept 2002 | - | $2.81 M(-4.9%) | $11.90 M(+3.0%) |
| June 2002 | - | $2.96 M(-13.1%) | $11.55 M(+5.2%) |
| Mar 2002 | - | $3.40 M(+24.5%) | $10.98 M(+14.3%) |
| Dec 2001 | $9.61 M(+15.6%) | $2.73 M(+11.0%) | $9.61 M(-2.9%) |
| Sept 2001 | - | $2.46 M(+3.3%) | $9.89 M(+7.5%) |
| June 2001 | - | $2.38 M(+17.3%) | $9.20 M(+7.5%) |
| Mar 2001 | - | $2.03 M(-32.7%) | $8.56 M(-10.4%) |
| Dec 2000 | $8.31 M(+29.8%) | $3.02 M(+70.7%) | $9.55 M(+16.0%) |
| Sept 2000 | - | $1.77 M(+1.6%) | $8.24 M(+2.1%) |
| June 2000 | - | $1.74 M(-42.5%) | $8.07 M(+3.1%) |
| Mar 2000 | - | $3.03 M(+78.0%) | $7.83 M(+5.8%) |
| Dec 1999 | $6.40 M(+10.3%) | $1.70 M(+6.3%) | $7.40 M(+4.2%) |
| Sept 1999 | - | $1.60 M(+6.7%) | $7.10 M(+4.4%) |
| June 1999 | - | $1.50 M(-42.3%) | $6.80 M(-2.9%) |
| Mar 1999 | - | $2.60 M(+85.7%) | $7.00 M(+20.7%) |
| Dec 1998 | $5.80 M(0.0%) | $1.40 M(+7.7%) | $5.80 M(+3.6%) |
| Sept 1998 | - | $1.30 M(-23.5%) | $5.60 M(-1.8%) |
| June 1998 | - | $1.70 M(+21.4%) | $5.70 M(0.0%) |
| Mar 1998 | - | $1.40 M(+16.7%) | $5.70 M(-1.7%) |
| Dec 1997 | $5.80 M(-1.7%) | $1.20 M(-14.3%) | $5.80 M(-3.3%) |
| Sept 1997 | - | $1.40 M(-17.6%) | $6.00 M(0.0%) |
| June 1997 | - | $1.70 M(+13.3%) | $6.00 M(-52.8%) |
| Mar 1997 | - | $1.50 M(+7.1%) | $12.70 M(0.0%) |
| Dec 1996 | $5.90 M(+1.7%) | $1.40 M(0.0%) | $12.70 M(+1.6%) |
| Sept 1996 | - | $1.40 M(-83.3%) | $12.50 M(0.0%) |
| June 1996 | - | $8.40 M(+460.0%) | $12.50 M(+119.3%) |
| Mar 1996 | - | $1.50 M(+25.0%) | $5.70 M(-1.7%) |
| Dec 1995 | $5.80 M(-31.8%) | $1.20 M(-14.3%) | $5.80 M(-18.3%) |
| Sept 1995 | - | $1.40 M(-12.5%) | $7.10 M(-7.8%) |
| June 1995 | - | $1.60 M(0.0%) | $7.70 M(-8.3%) |
| Mar 1995 | - | $1.60 M(-36.0%) | $8.40 M(-1.2%) |
| Dec 1994 | $8.50 M(-81.6%) | $2.50 M(+25.0%) | $8.50 M(-82.2%) |
| Sept 1994 | - | $2.00 M(-13.0%) | $47.70 M(+0.8%) |
| June 1994 | - | $2.30 M(+35.3%) | $47.30 M(-14.6%) |
| Mar 1994 | - | $1.70 M(-95.9%) | $55.40 M(-13.8%) |
| Dec 1993 | $46.30 M(+66.5%) | $41.70 M(+2506.3%) | $64.30 M(+111.5%) |
| Sept 1993 | - | $1.60 M(-84.6%) | $30.40 M(-16.3%) |
| June 1993 | - | $10.40 M(-1.9%) | $36.30 M(+13.1%) |
| Mar 1993 | - | $10.60 M(+35.9%) | $32.10 M(+15.5%) |
| Dec 1992 | $27.80 M(+742.4%) | $7.80 M(+4.0%) | $27.80 M(+36.3%) |
| Sept 1992 | - | $7.50 M(+21.0%) | $20.40 M(+38.8%) |
| June 1992 | - | $6.20 M(-1.6%) | $14.70 M(+61.5%) |
| Mar 1992 | - | $6.30 M(+1475.0%) | $9.10 M(+225.0%) |
| Dec 1991 | $3.30 M(+94.1%) | $400.00 K(-77.8%) | $2.80 M(+16.7%) |
| Sept 1991 | - | $1.80 M(+200.0%) | $2.40 M(+300.0%) |
| June 1991 | - | $600.00 K | $600.00 K |
| Dec 1990 | $1.70 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual SG&A year-on-year change?
- What is Regeneron Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly SG&A year-on-year change?
- What is Regeneron Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM SG&A year-on-year change?
What is Regeneron Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of REGN is $2.63 B
What is the all time high annual SG&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual selling, general & administrative expenses is $2.63 B
What is Regeneron Pharmaceuticals annual SG&A year-on-year change?
Over the past year, REGN annual selling, general & administrative expenses has changed by +$515.40 M (+24.36%)
What is Regeneron Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of REGN is $714.40 M
What is the all time high quarterly SG&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $758.80 M
What is Regeneron Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, REGN quarterly selling, general & administrative expenses has changed by +$73.90 M (+11.54%)
What is Regeneron Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of REGN is $115.41 B
What is the all time high TTM SG&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM selling, general & administrative expenses is $2.90 B
What is Regeneron Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, REGN TTM selling, general & administrative expenses has changed by +$112.86 B (+4418.71%)